Dechra Pharmaceuticals (DPH) Receives Average Recommendation of “Buy” from Analysts

Dechra Pharmaceuticals (LON:DPH) has received an average recommendation of “Buy” from the seven brokerages that are covering the company, reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is GBX 2,121.17 ($29.31).

A number of equities research analysts have recently weighed in on DPH shares. Numis Securities restated an “add” rating and issued a GBX 2,260 ($31.22) price objective on shares of Dechra Pharmaceuticals in a report on Thursday, January 18th. Royal Bank of Canada restated a “sector perform” rating and issued a GBX 2,400 ($33.16) price objective on shares of Dechra Pharmaceuticals in a report on Monday, February 26th. Finally, Jefferies Group restated a “hold” rating and issued a GBX 2,221 ($30.69) price objective on shares of Dechra Pharmaceuticals in a report on Wednesday, January 17th.

How to Become a New Pot Stock Millionaire

Shares of DPH opened at GBX 2,628 ($36.31) on Monday. Dechra Pharmaceuticals has a twelve month low of GBX 1,622 ($22.41) and a twelve month high of GBX 2,720 ($37.58).

The company also recently disclosed a dividend, which will be paid on Friday, April 6th. Stockholders of record on Thursday, March 8th will be issued a GBX 7.33 ($0.10) dividend. The ex-dividend date is Thursday, March 8th. This represents a dividend yield of 0.29%.

ILLEGAL ACTIVITY NOTICE: “Dechra Pharmaceuticals (DPH) Receives Average Recommendation of “Buy” from Analysts” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at

About Dechra Pharmaceuticals

Dechra Pharmaceuticals plc develops, manufactures, sells, and markets veterinary pharmaceuticals and related products for veterinarians worldwide. The company operates through the European Pharmaceuticals, the North American Pharmaceuticals, and the Pharmaceuticals Research and Development segments. It offers various endocrinology, dermatology and care, anesthesia and analgesia, cardiovascular disease, ophthalmology, and equine medicine products; food producing animal antimicrobials; poultry vaccines; and pet diets.

Analyst Recommendations for Dechra Pharmaceuticals (LON:DPH)

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply